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Abstract
Background: Impact of minimized extracorporeal circulation (MECC) for coronary surgery on mortality remains
controversial and gender significantly influence outcome.
Methods: We analyzed 3,139 male patients undergoing elective coronary surgery between 01/2004 and 05/2009.
Using propensity score matching after binary logistic regression, 1,005 patients (from 1,119 patients) undergoing
surgery with MECC could be matched with 1,005 patients (from 2,020 patients) undergoing surgery with
conventional extracorporeal circulation (CECC). Primary outcome was 30-day mortality.
Results: Unadjusted 30-day mortality was 2.7% in patients with CECC and 0.8% in those with MECC (mean
difference -1.9%; p < 0.001). The adjusted mean difference (average treatment effect of the treated) after matching
was -1.5% (95% confidence interval (CI) -2.6 to -0.4; p = 0.006). Postoperative hospital stay was shorter in patients
operated with minimized systems (adjusted mean difference -0.8 days; 95% CI -1.46 to -0.09; p = 0.03) and
incidence of postoperative neurocognitive dysfunction was also lower (adjusted mean difference -1.3%; 95% CI -2.2
to -0.4; p = 0.001). Chest tube drainage (adjusted mean difference +22 mL; 95% CI -47 to 91; p = 0.5) and risk for
acute kidney injury, kidney injury and failure according to RIFLE criteria (adjusted mean difference -1.0%; 95% CI
-2.5 to 0.6; p = 0.24) proved to be insignificant between both groups. Apart from reduced 30-day mortality,
however, average treatment effects for intensive care unit stay, postoperative hospital stay, chest tube drainage
and kidney injury did not significantly differ.
Conclusion: Using propensity score analysis, we observed an association between MECC and reduced 30-day
mortality in men, but our results call for further analysis.
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Background
Coronary artery bypass grafting (CABG) with conven-
tional extracorporeal circulation (CECC) remains the
treatment of choice, in particular, for multivessel disease
[1,2]. Common side effects of CECC include systemic
inflammatory response and dysfunctional coagulation
pathways leading to potential end-organ failure.
Although the concept of minimized extracorporeal
circulation (MECC) was introduced more than ten years
ago, it has not gained widespread use. Whereas some
studies could demonstrate improved survival, reduced
systemic inflammation and reduced transfusion require-
ment after CABG with MECC [3,4], other reports failed
to confirm these results [5]. Limitations of many recent
studies arose from observational study design and lim-
ited number of patients. Both facts lead to biased (i.e.
selection bias) results and lack of power, which in turn
made definitive conclusions for MECC use difficult, in
particular for determining postoperative mortality [6].
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Our institution has been using MECC for more than ten
years and we could show that MECC is a safe alternative
extracorporeal circulation (ECC) system and even high-
risk patients can undergo CABG with MECC [7].
Gender significantly impacts outcome after CABG and
women were shown to have increased mortality and
morbidity even after risk adjustment [8]. However, the
reasons for gender-related differences in outcome after
CABG surgery still remain controversial and vastly
unknown, but agreement exists on strong gender-related
bias in observational trials [9]. Most studies that exam-
ined gender differences in CABG surgery compared
conventional ECC with off-pump coronary artery bypass
grafting or analyzed it in patients undergoing CABG
with conventional ECC.
The objective of this study was to evaluate the impact
of minimized ECC and CECC use on mortality in males
undergoing elective CABG. A propensity score based
approach was used to estimate treatment effects of
MECC in men. We excluded women because it has
been previously shown that matching efficiency was very
low (26%) if propensity scores are used which contain
gender as a covariate [10]. This fact is reflective of the
vastly dissimilar preoperative profiles of women and
men and thus leads to little overlap of scores, which
limits the number of matching pairs.
Methods
Patients and study design
This is an observational retrospective study with 3,139
male patients, who underwent elective coronary artery
bypass grafting with conventional or minimized extra-
corporeal circulation between January 2004 and May
2009 at the University Medical Center Regensburg. The
study was approved by the university’s ethics board, the
individual patient consent was waived because of the
study’s retrospective design and data collection from
routine care. Exclusion criteria were as follows: emer-
gent procedures, off-pump revascularization, redo sur-
gery and preoperative renal replacement therapy.
Patients with severe aortic regurgitation and a body
mass index BMI ≥ 35 kg × m-2 were contraindications
for MECC use.
To avoid strong gender-related bias, we excluded
female patients from this study.
Data collection, variable definitions and study endpoints
Data were collected in and extracted from the institu-
tion’s database and from medical records. Variables
were defined according the European System for Car-
diac Operative Risk Evaluation (EuroSCORE) and perio-
perative mortality was calculated with the logistic
version of this risk model [11]. Serum creatinine was
measured in mg/dL at the day of admission and
glomerular filtration rate (in mL × min-1 × 1.73 m-2)
was estimated with the MDRD-equation (eGFR = 186.3
× SCr-1.154 × age-0.203) [12].
Primary endpoint was 30-day mortality. Secondary
outcome variables were intensive care unit stay, post-
operative stay, acute kidney injury (AKI) and severe neu-
rocognitive dysfunction (prolonged ischemic neurologic
deficit (PRIND), stroke). The RIFLE criteria [13] were
used to estimate acute kidney failure within the first 72
postoperative hours. The highest serum creatinine value
measured in this time was used to calculate relative
changes to baseline creatinine before operation and to
assign a patient into the appropriate group (risk, injury
and failure). The term “reperfusion time” refers to the
span between end of myocardial ischemia and end of
cardiopulmonary bypass irrespective of CECC or MECC
use.
Surgical procedure
After full median sternotomy, patients were connected
to the MECC system (MAQUET-System, Hechingen,
Germany), a fully closed circuit without blood-air con-
tact. Heparin (125 IE/kg) was administered following
preparation of left internal mammary artery (LIMA) to
target an activated clotting time (ACT) between 250 to
300 seconds. Calafiore’s blood cardioplegia was used for
cardiac arrest in all MECC patients. Further technical
details have been previously reported [14].
For conventional ECC heparin (350 IE/kg) was admi-
nistered after LIMA harvest and an ACT of ≥ 450 sec-
onds was targeted. Cardiac arrest was achieved with
Bretschneider’s solution in 96% of patients undergoing
CABG with CECC.
The ascending aorta and the right atrium (with a two-
stage cannula) were cannulated in all patients. All opera-
tions were performed with mild hypothermia (34°C).
After surgery all patients were transferred to the inten-
sive care unit and received standard hemodynamic
monitoring.
All operations were performed by six senior cardiac
surgeons, who were experienced with both MECC and
CECC. The proportion of MECC procedures did not
significantly differ between surgeons and all also oper-
ated a similar proportion of patients with CECC.
Impaired quality of coronary anatomy, diffuse vessel
pathology or more distal stenoses did not exclude
MECC use. Only 9.4% (n = 190) of CECC patients were
training procedures for residents and resulted in a
slightly lower use of LIMA. The final decision whether
to use MECC or not was left to the surgeon.
Statistical analysis
Statistical analysis was done with Stata 10.1 SE (Stata-
Corp., College Station, USA). Stata’s module psmatch2
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[15] was used for propensity score matching and covari-
ate imbalance testing. Continuous variables were first
tested for normality with the Shapiro-Wilk test and with
Quantile-Quantile-plots. If normally distributed, they are
presented as means ± standard deviations, otherwise as
median with interquartile range (25th and 75th percen-
tile). Student’s t-test was used for comparison of two
continuous, normally distributed variables, whereas Wil-
coxon’s ranksum test was used for non-normally distrib-
uted variables. Categorical data were shown as
frequency distributions and analyzed with Fisher’s exact
test (in a 2 × 2 table) or with the Chi-square test.
Because patients in this study were not randomly
assigned to CABG with MECC, we matched patients
based on their propensity (conditional probability) to
undergo CABG with MECC. The propensity score (PS)
is a subject’s probability of receiving a specific treat-
ment conditional on the observed covariates [16]. The
propensity score was calculated by binary logistic
regression including all variables marked with an aster-
isk in Table 1. Nearest neighbor matching with a cali-
per ε = 0.2 × sP (sP denotes standard deviation of the
estimated PS) was used to match 1,005 patients in the
MECC group to 1,005 patients from the ECC group
(matching efficiency 89.8%; 1,005/1,119 of MECC
patients; 1,005 pairs). We used non-replacement that
is, once a treated case is matched to one non-treated
case, both cases were removed from the pool. We
defined logit = log ((1-PS)/PS) as propensity score and
used it for matching. The logit of PS is called linear
predictor of the PS.
Before matching the mean PS for MECC use in men
operated with conventional ECC (n = 2,020) was 0.3281
± 0.1142 and in those receiving CABG with MECC
0.3914 ± 0.1145 with an associated standardized differ-
ence of 55% (95% CI 48 to 63; t test p-value < 0.001).
After matching, the mean PS for MECC use in the
matched patients not receiving MECC was 0.3827 ±
0.1049 and in those receiving MECC was 0.3875 ±
0.1108, which yielded a standardized difference of 4.2%
(95% CI -4.3 to 13.1; p > 0.05 for a two-tailed test). Fig-
ure 1 displays the distributions of estimated propensity
scores stratified to treatment (MECC) or control
(CECC) group.
Table 1 Unadjusted pre- and operative baseline data
Variable CECC
(n = 2,020)
MECC
(n = 1,119)
p-value
Age [years] 65.5 ± 8.7 66.1 ± 8.8 0.05*
Age group [n;%]
< 59 469 (23) 250 (22) 0.06
60-69 821 (41) 435 (39)
70-79 688 (34) 393 (35)
> 80 42 (2) 41 (4)
Logistic EuroSCORE [%, 95% CI)A 3.2 (3.0 to 3.4) 3.2 (3.0 to 3.4) 0.16
No of distal anastomoses [n] 3 (3; 4)
Range (1-8)
3 (3; 4)
Range (1-6)
< 0.001*
Use of LIMA [%] 88.3 93.6 < 0.001*
Bypass time [min] 95 ± 31 84 ± 26 < 0.001*
Aortic cross clamp time [min] 57 ± 19 51 ± 17 < 0.001*
Reperfusion time [min] 34 ± 12 28 ± 12 < 0.001*
Ejection fraction [%] 62 (49; 70) 63 (50; 70) 0.12
Body mass index [kg × m-2] 28.4 ± 3.8 28.2 ± 3.5 0.65*
Body surface area [m2] 1.97 ± 0.16 1.95 ± 0.14 < 0.001*
Hemoglobin [mg × dL-1] 13.0 ± 1.5 13.1 ± 1.5 0.02*
Leukocytes [n × 10-9 L] 7.9 (6.7; 9.3) 7.7 (6.6; 9.2) 0.16
Thrombocytes [n × 10-9 L] 251 (210; 290) 248 (206; 292) 0.06
Arterial hypertension [%] 74.4 79.9 < 0.001*
COPD [%] 8.6 9.0 0.69
Atrial fibrillation [%] 3.8 3.3 0.48
Peripheral vascular disease [%] 6.9 6.0 0.32
Insulin-dependent diabetes [%] 27.5 28.8 0.45
Serum creatinine [mg × dL-1] 1 (0.9; 1.2) 1 (0.9; 1.1) 0.15
Estimated GFRB < 60 mL × min-1 × 1,73 m-2 [%] 16.4 18.4 0.14
ACI confidence interval
BGFR glomerular filtration rate
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Covariate balance was tested using the standardized
difference before and after matching together with the
achieved percentage reduction in absolute bias. The
standardized difference is the difference of the sample
means in the treated and non-treated sub-samples as a
percentage of the square root of the average of the sam-
ple variances in the treated and non-treated groups.
The average treatment effect for the treated (ATT)
answers the question: Is MECC beneficial for those indi-
viduals, who were (not randomly) assigned to treatment,
i.e. MECC and was estimated with Wilcoxon’s signed
rank test for continuous variables or with McNemar’s
test for risk differences for binary outcomes to account
for the paired data structure after matching. We also
calculated the average treatment effect (ATE) that
answers the question if MECC is beneficial for those
randomly drawn from the overall population. Bootstrap-
ping (400 replications) was used to estimate 95% CIs for
ATEs. The key notion is ATT ≠ ATE and they are
linked via ATE = N1/N × ATT + N0/N × ATU (N0
denotes the number of non-participants, N1 denotes the
number of participants and ATU the average treatment
effect for the non-participants).
Hidden bias was estimated according to Rosenbaum’s
sensitivity analysis. We used Stata’s module rbounds
[17] for this test.
A p-value < 0.05 was considered significant.
Results
Patient characteristics
Unadjusted baseline data were summarized in Table 1.
Several pre- and perioperative covariates were signifi-
cantly different between both groups and may reflect
the non-randomized design of this study. Patients with
MECC were slightly older, had a slightly lower median
number of distal anastomoses, a higher frequency of
LIMA use, shorter mean aortic cross-clamping and
reperfusion time, lower mean body surface areas and a
higher prevalence of arterial hypertension.
After matching, treated patients were similar with
regards to all baseline covariates used for PS estimation
(Table 2). Matching reduced covariate imbalance and
Figure 1 Distribution of estimated native propensity score (not the logit of PS) stratified to type of extracorporeal circulation. There is
a sufficient overlap of propensity scores between both groups. The lower panels show the density distributions of PS and the superimposed
normal curves. CECC-conventional extracorporeal circulation; MECC-minimized extracorporeal circulation; PS-propensity score.
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improved covariate balance across treatment groups.
The median absolute bias before matching was 17.6 and
after matching 1.43.
Outcome
The unadjusted 30-day mortality was 2.7% (55/2,020) in
the conventional ECC group and 0.8% (9/1,119) in the
MECC group (mean difference -1.9%; p < 0.001). The
adjusted mean difference in 30-day mortality after
matching confirms a survival benefit in patients, who
were primarily assigned to MECC (-1.5%; 95% CI -2.6 to
-0.4; p = 0.006). If randomly drawn from the overall
population, CABG with MECC even exerts a survival
benefit (ATE) of -1.9% (95% CI -2.9 to -1.0) because the
mean ATU was 2.2% and thus enforced the ATE.
Secondary outcome variables were summarized in
Table 3. Whereas intensive care unit stay was insignifi-
cant after adjustment for covariates, postoperative hospi-
tal stay was significantly lower in patients primarily
assigned to MECC (ATT). The observed effect, however,
was only marginal because the upper limit of the 95%
confidence interval almost touches zero or includes zero
(for the ATE). Severe neurocognitive dysfunction was
less likely to occur in the MECC group with an adjusted
mean difference of -1.3% (95% CI -2.2 to -0.4). Mean
chest tube drainage was insignificant between treatment
(MECC; 828 mL) and control group (CECC; 806 mL)
after matching (adjusted mean difference +22 mL; 95%
CI -47 to 91 mL; p = 0.50). The ATE for chest tube
drainage was +36 mL (95% CI -22 to 97 mL; p > 0.05
for a two-tailed test).
The unadjusted requirement of PRBC transfusion did
not differ between both groups (Table 4).
Renal function
We used the RIFLE criteria for evaluation of early acute
renal dysfunction within 72 hours after surgery. Before
matching 3.6% of men in the control group (n = 72)
and 2.4% (n = 26) in the treatment group were at least
at risk for AKI (difference -1.2%; p = 0.08). After
Table 2 Covariate balance testing between unmatched and matched sample
Variable Standardized difference [%] % reduction |difference| p-value
Unmatched Matched Unmatched Matched
Age 8.1 0.1 98.3 0.03 0.97
No of grafts -21.5 3.9 82.1 < 0.001 0.37
LIMA use 17.6 0.7 96.0 < 0.001 0.86
ECC-timeA -38.3 1.4 96.5 < 0.001 0.72
Cross clamp time -26.9 3.3 87.8 < 0.001 0.42
Reperfusion time -39.4 -1.5 96.3 < 0.001 0.68
Body mass index 1.5 1.0 32.6 0.65 0.61
Body surface area -16.6 4.0 76.0 < 0.001 0.36
Hypertension 15.2 -1.4 90.6 < 0.001 0.74
AECC extracorporeal circulation
Table 3 Estimated average treatment effects on several outcome variables
Comparison Outcome measures
ATTA 30-day
mortality [%]
ICU stay
[days]
Postoperative hospital
stay [days]
Postoperative neuro-cognitive
dysfunction [%]
CECC versus MECC
CECC (n = 2,020) 2.7 2.6 12.9 1.1
MECC (n = 1,119) 0.8 2.2 12.0 0.2
Unadjusted mean difference -1.9 -0.4 -0.9 -0.9
p-value < 0.001 < 0.001 < 0.001 0.003
Adjusted mean difference after matching of 1,005 pairs
(95% confidence interval)
-1.5 (-2.6 to
-0.4)
-0.38 (-0.80 to
0.00)
-0.81 (-1.46 to -0.09) -1.3 (-2.2 to -0.4)
p-value 0.006 0.050 0.03 0.001
ATEB
Adjusted mean difference with 95% bias corrected
confidence interval
-1.9 (-2.9 to
-1.0)C
-0.36 (-0.72 to
0.01)D
-0.74 (-1.31 to 0.1)D -1.0 (-1.70 to -0.4)C
A - ATT Average treatment effect for the Treated
B - ATE Average treatment effect
C - The 95% confidence interval does not include a zero, or p < 0.05 for a two-tailed test
D - The 95% confidence interval does include a zero, or p > 0.05 for a two-tailed test
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matching 3.5% of men in the control and 2.5% of men
in the MECC group were at least at risk for AKI
(adjusted difference -1.0%; 95% CI -2.5 to 0.6; p = 0.24).
The ATE was calculated as -1.2% (95% bias corrected
confidence interval -2.8 to 0.04; p > 0.05 for a two-tailed
test). Thus, MECC did not significantly reduce early
postoperative renal dysfunction with regards to risk for
AKI, kidney injury and failure.
However, significantly fewer men in the MECC group
required renal replacement therapy (RRT) during the
entire hospital stay (1.16% versus 2.43%; p = 0.015).
Sensitivity analysis
Since selection bias remains the most challenging analy-
tic problem in observational studies, we conducted a
sensitivity analysis using Rosenbaum’s approach. Using
Wilcoxon’s signed rank test, the sensitivity analysis
showed that our study becomes sensitive to hidden bias
at Γ = 1.5 for 30-day mortality, at Γ = 1.6 for intensive
care unit stay, at Γ = 1.3 for postoperative hospital stay
and for Γ = 1.6 for severe postoperative neurocognitive
dysfunction. Because these values are small, we conclude
that the study is very sensitive to hidden bias and there-
fore further analysis that controls for additional biases is
warranted.
Discussion
Propensity score methods are increasingly being used to
reduce the impact of treatment-selection bias in the esti-
mation of causal treatment effects in observational stu-
dies [16]. We used propensity score matching to
estimate for the first time the treatment effect of MECC
for CABG in a large sample of men. We could show
that MECC significantly reduces 30-day mortality in
men with an average treatment effect of -1.9%. Our
results confirm previous randomized studies that
showed improved survival of MECC [18,19] without dif-
ferentiating between men and women. The reported
ATE might seem low, but if assuming several hundred
CABG in men per year, it could directly translate into
many saved lives. However, even advanced statistical
methods to adjust imbalance between treatment and
control group in observational studies cannot compen-
sate the current lack of at least one sufficiently powered
randomized multicenter study to estimate the outcome
of CABG after MECC irrespective of gender. Using our
unadjusted 30-day mortality data (2.7% versus 0.8%), at
least 850 male patients per group remain necessary in a
randomized study to detect this difference with a power
of 80% and at a significance level of 0.05. However, the
mechanism why MECC might be associated with
reduced mortality still is speculative and ranges from
improved myocardial protection through consequent use
of blood cardioplegia, reduced transfusion requirement
to selection of healthier patients.
Current critics of MECC also may question whether
small survival benefits justify a more complex procedure
with learning curves and a more intense and challenging
interplay between surgeon, anesthesiologist and
perfusionist.
Analysis of other outcome variables showed that apart
from postoperative neurocognitive dysfunction, intensive
care stay and postoperative hospital stay largely
remained uninfluenced by MECC. In addition, chest
tube drainage and early postoperative kidney injury
(AKI) yielded comparable results between MECC and
CECC. One reason for the latter disparity may derive
from different use of AKI definitions in previous studies,
different protocols for extracorporeal perfusion at differ-
ent institutions, but results are difficult to compare
because of heterogeneous patient populations and differ-
ent MECC systems.
We also could not demonstrate a lower transfusion
requirement during entire hospital stay or reduced ven-
tilation time in our sample and thus our results clearly
contrast recent studies [3,20,21]. One reason originates
from the many observational trials with MECC and the
unavoidable selection bias in these studies, but without
necessarily overestimating the magnitude of the effects
of treatment. Second most of RCTs with MECC were
underpowered to detect true treatment effects with
regards to mortality or other “hard” endpoints because
Table 4 Unadjustedperi- and postoperative data
Variable CECC (n = 2,020) MECC (n = 1,119) p-value
Postoperative dialysis during entire
hospital stay [%]
2.4 1.2 0.015
Drain loss [mL] 600 (490; 900) 650 (480; 950) 0.013
Frequency of PRBCA transfusion [%] 44.7 41.7 0.10
No of transfused PRBC [n] 2 (1; 4) 2 (1; 3) 0.001
Frequency of FFPB transfusion [%] 19.3 21.8 0.09
No of transfused FFP [n] 4 (3; 7) 5 (3; 8) 0.11
Ventilation time [min] 12 (8; 16) 11 (8; 15) 0.11
APRBC packed red blood cells
BFFP fresh frozen plasma
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of different causes, e.g. distinctive study objectives or a
low number of patients.
The clinical impact of lower creatinine kinase MB,
troponin and maximal lactate release after MECC is still
under debate and may rather reflect intraoperative iso-
volumetric perfusion than improved outcome [20,21].
The rationale for improved neurocognitive outcome for
MECC patients most likely derives from improved cere-
bral microcirculation and decreased microembolization
[22], but further research remains necessary to confirm
these results.
It was assumed that different types of cardioplegia
(crystalloid versus blood) were at least in part responsi-
ble for this disparity, but a recent RCT only demon-
strated marginal effects [23] between both types of
cardioplegia and thus its impact might be overestimated.
Although a recent meta-analysis [24] could demon-
strate slightly reduced PRBC transfusion requirement
and PRBC transfusion per patient, we could not confirm
this findings in our large sample, in particular when the
entire hospital stay is considered.
Limitations
Findings from propensity score analyses might be poten-
tially limited by biases related to unmeasured and hid-
den covariates [[16], 25]. Since our sensitivity analysis
showed low Γ-values for several outcome variables, it is
likely that unmeasured variables contribute to our
results and require further research. Incomplete or inex-
act matching might also affect the results of our study.
However, we could match almost 90% of our MECC
patients and the overlap of propensity scores was large.
This contrasts other PS studies with a matching effi-
ciency < 60%.
Conclusions
We observed an association between MECC use for
CABG and decreased 30-day mortality by using a pro-
pensity score analysis in a large cohort of male patients.
It is tempting to suggest that men should undergo elec-
tive CABG with MECC, but the findings of our study,
based on a non-randomized design, are largely hypoth-
esis generating and call for at least one randomized,
multicenter clinical trial using a current risk score for
precise uniform evaluation of coronary pathology and
predefined criteria for perioperative care.
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